Liège

Futó vizsgálatok

• Toboroz

  AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

  NCT07611110· 3. fázis· Forrás

• Fut, nem toboroz

  Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

  NCT06473779· 3. fázis· Forrás

• Toboroz

  Observational Study Protocol: LIVER-R

  NCT06252753· Forrás

• Fut, nem toboroz

  A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice.

  NCT05637112· Forrás

• Fut, nem toboroz

  Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

  NCT04784715· 3. fázis· Forrás

• Fut, nem toboroz

  Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC

  NCT04550260· 3. fázis· Forrás

• Fut, nem toboroz

  A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors

  NCT04482309· 2. fázis· Forrás

• Fut, nem toboroz

  Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

  NCT04494425· 3. fázis· Forrás

• Fut, nem toboroz

  To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

  NCT03330847· 2. fázis· Forrás

• Fut, nem toboroz

  Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

  NCT02453282· 3. fázis· Forrás

• Fut, nem toboroz

  An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

  NCT02213926· 2. fázis· Forrás

• Fut, nem toboroz

  Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.

  NCT00099437· 3. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Máj- és epeúti rák1 toboroz
• Prosztatarák1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Lezárult

  ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors

  NCT06973161· Forrás

• Lezárult

  A Study for Observing Severe Asthma in Patients Treated With Tezepelumab

  NCT05677139· Forrás

• Lezárult

  BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging

  NCT05552508· 4. fázis· Forrás

• Lezárult

  Study to Evaluate Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma

  NCT05274815· 3. fázis· Forrás

• Lezárult

  Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)

  NCT04609878· 3. fázis· Forrás

• Lezárult

  Patient-reported Outcomes in Real-world Use of Benralizumab in Patients With Severe Eosinophilic Asthma in Belgium

  NCT04221802· Forrás

• Lezárult

  AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

  NCT02296125· 3. fázis· Forrás